Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the feasibility and safety of delegating remote biological monitoring in post-hospitalization for cardiac decompensation by a heart failure nurse.
Chronic heart failure is a major public health issue in France. It is the leading cause of hospitalisation in people over 65 years of age and results in many costly and potentially avoidable hospital stays. One third of patients are readmitted to hospital within 3 months of discharge.
A remote monitoring programme and natriuretic peptide monitoring during this vulnerable period can help improve patient management, reducing rehospitalisation rates, emergency room visits and mortality.
Given the increasing pressure on already limited healthcare resources, it is important to examine the delegation of care to specialist nurses, as well as their safety.
This study aims to evaluate the feasibility and safety of delegating remote biological monitoring in post-hospitalization for cardiac decompensation by a heart failure nurse.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remote biological monitoring by a heart failure nurse | Other | Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3. |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the concordance, appropriateness and safety of nursing decisions in post-hospitalization heart failure | The relevance and safety of IDE decisions will be determined by the concordance rate between the decisions made by the cardiologist and the IDE following the biological results at each check-up and after blind review by a second cardiologist | At the end of the patient's follow-up, an average of 3 month |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the risk of rehospitalisation in the study population between discharge and M3 | The risk of rehospitalization and death will be assessed, to see if a significant difference is observed between IDE decisions and cardiologist decisions, with items listed below :
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients discharged from the cardiology department of NOVO Hospital with a heart failure episode
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Morgane Gessat | Hospital NOVO - Pontoise site | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardiology department - Hospital NOVO - Pontoise site | Pontoise | 95300 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23186936 | Background | Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, Galinier M, Mulak G, Donal E, Delahaye F, Juilliere Y, Damy T, Jourdain P, Bauer F, Eicher JC, Neuder Y, Trochu JN; Heart Failure of the French Society of Cardiology. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013 Apr;15(4):465-76. doi: 10.1093/eurjhf/hfs189. Epub 2012 Nov 27. | |
| 33866827 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| At the end of the patient's follow-up, an average of 3 month |
| Assessment of the risk of death in the study population between discharge and M3 | The risk of death will be assessed by the rate of death for all-cause and cardiac to see if a significant difference is observed between IDE decisions and cardiologist decisions. | At the end of the patient's follow-up, an average of 3 month |
| Impact of the organisation on patient outcomes at M3 (Brain natriuretic peptide) | The impact of the organisation, favourable or unfavourable, on patient outcomes will be assessed by the evolution of the following item : - Brain natriuretic peptide levels between discharge and three months, | At the end of the patient's follow-up, an average of 3 month |
| Impact of the organisation on patient outcomes at M3 (New York Heart Association (NYHA)) | The impact of the organisation, favourable or unfavourable, on patient outcomes will be assessed by the evolution of the following item : - New York Heart Association (NYHA) score from discharge to three months. | At the end of the patient's follow-up, an average of 3 month |
| Assessment of the feasibility of the patient monitoring system | The feasibility of the patient monitoring system will be assessed in relation to the number of biological tests not performed. If the number of biological tests not performed is too high, the patient monitoring system will not be validated. | At the end of the patient's follow-up, an average of 3 month |
| Background |
| Khan MS, Sreenivasan J, Lateef N, Abougergi MS, Greene SJ, Ahmad T, Anker SD, Fonarow GC, Butler J. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail. 2021 Apr;14(4):e008335. doi: 10.1161/CIRCHEARTFAILURE.121.008335. Epub 2021 Apr 19. |
| 28638496 | Background | Health Quality Ontario. Effect of Early Follow-Up After Hospital Discharge on Outcomes in Patients With Heart Failure or Chronic Obstructive Pulmonary Disease: A Systematic Review. Ont Health Technol Assess Ser. 2017 May 25;17(8):1-37. eCollection 2017. |
| 21098580 | Background | Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, Boll H, Kim SS, Koehler K, Lucke S, Honold M, Heinze P, Schweizer T, Braecklein M, Kirwan BA, Gelbrich G, Anker SD; TIM-HF Investigators. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail. 2010 Dec;12(12):1354-62. doi: 10.1093/eurjhf/hfq199. |
| 17448376 | Background | Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007 Apr 24;49(16):1733-9. doi: 10.1016/j.jacc.2006.10.081. Epub 2007 Apr 2. |